Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study

Cost-Effectiveness of Alirocumab

(2019) Dhruv S. Kazi et al.   ANNALS OF INTERNAL MEDICINE

Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

(2019) Guy De Backer et al.   ATHEROSCLEROSIS

Lipid levels achieved after a first myocardial infarction and the prediction of recurrent atherosclerotic cardiovascular disease

(2019) Joel Ohm et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines

(2019) Salim S. Virani et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe

(2018) Jean Ferrieres et al.   European Journal of Preventive Cardiology

Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab

(2018) Arman Qamar et al.   JAMA Cardiology

Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial

(2017) Dhruv S. Kazi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease

(2017) Christopher P. Cannon et al.   JAMA Cardiology

Reductions in Atherogenic Lipids and Major Cardiovascular EventsClinical Perspective

(2016) Kausik K. Ray et al.   CIRCULATION

Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents

(2016) Paul M Ridker et al.   EUROPEAN HEART JOURNAL

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

(2015) Dean J. Kereiakes et al.   AMERICAN HEART JOURNAL

Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients

(2015) Olivier Descamps et al.   ATHEROSCLEROSIS

Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

(2014) S. Matthijs Boekholdt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL

The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)

(2010) T. Jernberg et al.   HEART